A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

Ritesh R. Kotecha, Sahil D. Doshi, Andrea Knežević, Joshua Chaim, Ying‐Bei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan Joseph McHugh, Neil J. Shah, Emily Feld, David H. Aggen, William Rafelson, Han Xiao, Maria I. Carlo, Darren R. Feldman, Chung‐Han Lee, Robert J. Motzer, Martin H. Voss